- Precio de cierre del día anterior
34.13 - Apertura
33.49 - Oferta 30.87 x 100
- Demanda 33.83 x 100
- Rango diario
31.92 - 33.59 - Rango de 52 semanas
20.02 - 37.59 - Volumen
1,283,069 - Volumen prom.
2,347,288 - Capitalización bursátil (intradiario)
9.151MM - Beta (mensual por 5 años) 0.51
- Índice de relación precio/utilidad (últimos doce meses)
20.67 - EPS (últimos doce meses)
1.55 - Fecha de utilidades 4 feb 2025 - 10 feb 2025
- Proyección de dividendo y rentabilidad --
- Fecha de exdividendo --
- Est. anual
35.24
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
www.exelixis.com1,310
Empleados a tiempo completo
31-diciembre
Fin del año fiscal
Sector
Industria
Noticias relacionadas
Más detallesInformación general del desempeño: EXEL
Retornos totales acumulados hasta el 24/1/2025, que pueden incluir dividendos u otras distribuciones. El punto de referencia es
.Retorno a la fecha
Retorno en 1 año(s)
Retorno en 3 año(s)
Retorno en 5 año(s)
Comparar con: EXEL
Puedes seleccionar hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.
Estadísticas: EXEL
Más detallesMedidas de valoración
Capitalización bursátil
9.75B
Valor de la empresa
8.75B
Precio/utilidad (últimos 12 meses)
22.02
Precio/beneficio estimado
19.84
Índice PEG (cálculo de 5 años)
2.27
Precio/Ventas (ttm)
4.94
Precio/reserva (TMR)
4.28
Valor de la empresa/Ingresos
4.20
Valor de la empresa/BAIIDA
13.76
Actividad financiera destacada
Rentabilidad y estado de resultados
Margen de ganancia
22.43%
Retorno de activos (ttm)
12.81%
Retorno sobre el capital (ttm)
20.20%
Ingresos (ttm)
2.08MM
Ingresos netos disponibles (ttm)
466.92M
BPA diluido (ttm)
1.55
Balance general y flujo de efectivo
Caja total (TMR)
1.19MM
Deuda/capital total (TMR)
8.55%
Flujo de caja disponible apalancado (ttm)
431.27M